Biotechnology
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to discuss its financial and operating results for the full fiscal year 2020, in addition to providing ...
2021-03-16 20:30
5683
QBiotics Welcomes TDM Growth Partners As Cornerstone Investor in a Capital Raise To Accelerate Drug Development Timelines
Key highlights: * QBiotics welcomes TDM Growth Partners as cornerstone investor * TDM Growth Partners is investing A$50 million into QBiotics to accelerate QBiotics' human drug development pipeline, support marketing of the company's veterinary pharmaceutical STELFONTA® and strengthen the QBi...
2021-03-16 06:35
3059
Microba Life Sciences partners with Unilever to target sleep through the gut microbiome
BRISBANE, Australia, March 15, 2021 /PRNewswire/ -- Experts in gut microbiome
analysis, Microba Life Sciences
2021-03-15 21:59
3359
BioVaxys Enters Major Bioproduction Agreement With Wuxi Biologics (Hong Kong) Ltd. To Synthesize Proteins For Its SARS-CoV-2 Vaccine And COVID-T™ Immunodiagnostic Programs
VANCOUVER, British Columbia, March 15, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into a major bioproduction agreement w...
2021-03-15 20:00
3600
Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal
HONG KONG, March 15, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-bindin...
2021-03-15 19:00
3449
Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal
HONG KONG, March 15, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-bindin...
2021-03-15 19:00
5407
Antengene Included in the Shenzhen-Hong Kong Stock Connect
SHANGHAI and HONG KONG, March 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and o...
2021-03-15 09:40
4904
Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea
SHANGHAI and SEOUL, South Korea, March 15, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematolo...
2021-03-15 08:00
4099
Medeze Commended by Frost & Sullivan for Dominating the Stem Cell Banking Market with Its Pioneering, Full Spectrum Services
Medeze's expansion strategies and customer-focused innovation in MSC banks and regenerative therapies have enabled it to garner a major share of the market SINGAPORE, March 12, 2021 /PRNewswire/ -- Based on its recent analysis of the Southeast Asia stem cell banking market, Frost & Sullivan recog...
2021-03-12 17:55
4329
Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines
SHANGHAI, March 11, 2021 /PRNewswire/ -- Delonix Bioworks Ltd. (Delonix), a biotechnology company dedicated to developing the next generation vaccines with synthetic biology approaches, has recently closed a$14 million Series Seed financing led by Boehringer Ingelheim Venture Fund (BIVF) and IDG ...
2021-03-11 21:21
1907
PharmAbcine to Present at AACR Annual Meeting 2021
DAEJEON, South Korea, March 11, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today an e-posterpresentation featuring nonclinical data of PMC-309 at American Association for Cancer Researc...
2021-03-11 21:00
1803
Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients
SUZHOU, China, March 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalut...
2021-03-11 14:54
5117
Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021
SUZHOU, China and ROCKVILLE, Md., March 11, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest preclinical...
2021-03-11 08:35
3479
Non-Invasive Liquid Biopsy to Help Cancer Diagnosis Gets CE Certification
LONDON, March 11, 2021 /PRNewswire/ -- Datar Cancer Genetics, a global leader in non-invasive cancer diagnostics, has received Conformité Européenne (CE) Mark for its innovative TruBlood solution, a new paradigm in cancer detection, diagnosis and management. TruBlood is a blood-based, non-invasi...
2021-03-11 07:00
3633
Viva Biotech Successfully Held 2021 Partnership Summit -- Novel Drug 2021, the Persistence and Transformation of Start-up Founders
SHANGHAI, March 10, 2021 /PRNewswire/ -- March 2nd-6th, 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including representatives from global investment institutions, R&D heads from pharmaceutical companies, and business development leader...
2021-03-10 20:18
7413
Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization
SHANGHAI, March 9, 2021 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases, today announced the completion of overUS$100 million Series B financing. The Series B round was led by Loyal Valley Capital...
2021-03-10 08:00
2299
Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients
* ALA-1000 is the first, three-month slow-release Buprenorphine injection. * Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. * ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treat...
2021-03-10 00:00
1768
Genome and Company signs second clinical trial collaboration and supply agreement (Phase 2) with Merck KGaA, Darmstadt, Germany and Pfizer for immuno-oncology microbiome study
* Genome and Company expands collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for further clinical combination study of GEN-001 in gastric cancers * Establishment of the efficient "clinical development strategy" for the global immuno-oncology microbiome treatment SEOUL, South Korea,...
2021-03-09 22:00
4301
Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs
HONG KONG, March 9, 2021 /PRNewswire/ -- Insilico Medicine, an AI drug discovery company, announced that UCB will integrate Insilico'sChemistry42™ into UCB's internal drug discovery pipeline. UCB's early adoption of Insilico Medicine's proprietary technology will provide UCB's scientists with the...
2021-03-09 22:00
2886
Novartis receives approval for Kymriah (tisagenlecleucel) by Health Sciences Authority as Singapore's first commercially approved CAR-T therapy
* Kymriah, the first chimeric antigen receptor T-cell (CAR-T) therapy approved inSingapore, is indicated as a one-time treatment manufactured individually for each patient. * Novartis works closely with qualified centres to deliver this treatment for eligible relapsed/refractory (r/r) pediatr...
2021-03-09 20:12
7056
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 286 media titles]
2025-12-10 16:00